Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | ACP3 | P15309 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | CASR | P41180 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30763462 | 1.00 | SIGMAR1 (0.61) | SIGMAR1ACP3CYP3A4CYP2D6CHRM2 | |
| SCHEMBL283979 | 1.00 | SIGMAR1 (0.61) | SIGMAR1ACP3CYP3A4CYP2D6CHRM2 | |
| SCHEMBL3749295 | 1.00 | SIGMAR1 (0.61) | SIGMAR1ACP3CYP3A4CYP2D6CHRM2 | |
| SCHEMBL8437895 | 1.00 | SIGMAR1 (0.61) | SIGMAR1ACP3CYP3A4CYP2D6CHRM2 | |
| Hydrochloric Acid SCHEMBL2469805 | 0.97 | SIGMAR1 (0.59) | SIGMAR1ACP3CYP3A4CYP2D6CHRM2 | |
| Hydrochloric Acid SCHEMBL607712 | 0.97 | SIGMAR1 (0.59) | SIGMAR1ACP3CYP3A4CYP2D6CHRM2 | |
| Hydrochloric Acid SCHEMBL3078151 | 0.97 | SIGMAR1 (0.59) | SIGMAR1ACP3CYP3A4CYP2D6CHRM2 | |
| SCHEMBL8433113 | 0.89 | SIGMAR1 (0.57) | SIGMAR1ACP3CYP3A4CYP2D6CHRM2 | |
| SCHEMBL278474 | 0.89 | SIGMAR1 (0.57) | SIGMAR1ACP3CYP3A4CYP2D6CHRM2 | |
| SCHEMBL8433689 | 0.89 | SIGMAR1 (0.57) | SIGMAR1ACP3CYP3A4CYP2D6CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111193069-B | Electrolyte for electrochemical device, method for preparing the same, and electrochemical device | 三星电子株式会社 | 2024-11-01 | — | — | CN | claimed |
| US-11643398-B2 | Metallic salt containing anion having heterocyclic aromatic structure, method of preparing the metallic salt, and electrolyte and electrochemical device each including the metallic salt | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-05-09 | — | — | US | claimed |
| EP-3657590-B1 | METALLIC SALT CONTAINING ANION HAVING HETEROCYCLIC AROMATIC STRUCTURE, METHOD OF PREPARING THE SAME, AS WELL AS ELECTROLYTE AND ELECTROCHEMICAL DEVICE EACH INCLUDING THE METALLIC SALT | SAMSUNG ELECTRONICS CO LTD (KR) | 2023-04-26 | — | — | EP | claimed |
| CN-114539460-A | Method for synthesizing macromolecule loaded asymmetric catalyst | 哈尔滨工业大学（深圳） | 2022-05-27 | — | — | CN | claimed |
| EP-3657590-A1 | METALLIC SALT CONTAINING ANION HAVING HETEROCYCLIC AROMATIC STRUCTURE, METHOD OF PREPARING THE SAME, AS WELL AS ELECTROLYTE AND ELECTROCHEMICAL DEVICE EACH INCLUDING THE METALLIC SALT | Samsung Electronics Co., Ltd. (KR) | 2020-05-27 | — | — | EP | claimed |
| CN-111193069-A | Metal salt, method for preparing metal salt, and electrolyte and electrochemical device each containing metal salt | 三星电子株式会社 | 2020-05-22 | — | — | CN | claimed |
| US-20200157058-A1 | METALLIC SALT CONTAINING ANION HAVING HETEROCYCLIC AROMATIC STRUCTURE, METHOD OF PREPARING THE METALLIC SALT, AND ELECTROLYTE AND ELECTROCHEMICAL DEVICE EACH INCLUDING THE METALLIC SALT | SAMSUNG SDI CO., LTD. (KR) | 2020-05-21 | — | — | US | claimed |
| US-8853390-B2 | Processes for preparing 1,2-substituted cyclopropyl derivatives | ABBVIE INC. (US) | 2014-10-07 | — | — | US | claimed |
| WO-2012037258-A1 | PROCESSES FOR PREPARING 1,2-SUBSTITUTED CYCLOPROPYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2012-03-22 | — | — | WO | claimed |
| US-8084630-B2 | Process for the synthesis of ramelteon and its intermediates | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-12-27 | — | — | US | claimed |
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-12 | — | — | US | claimed |
| EP-2098519-A1 | Process for the synthesis of ramelteon and its intermediates | Teva Pharmaceutical Industries Ltd. (IL) | 2009-09-09 | — | — | EP | claimed |
| WO-2009056993-A2 | A PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-07 | — | — | WO | claimed |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | US | claimed |
| US-6060617-A | REACTING AN ALKALI METAL HYDRIDE AND ALKALI METAL AMIDES WITH A SUBSTITUTED AMINE IN AN ETHER SOLVENT IN ABSENCE OF AN ELECTRON CARRIER TO PRODUCE AN ALKALI METAL AMIDE FREE OF ORGANIC CONTAMINANTS | FMC CORPORATION (US) | 2000-05-09 | — | — | US | claimed |
| EP-0843682-A1 | HIGH PURITY FORMULATIONS OF HIGHLY SUBSTITUTED LITHIUM AMIDE BASES | FMC CORPORATION (US) | 1998-05-27 | — | — | EP | claimed |
| US-5726308-A | High purity formulations of highly substituted lithium amide bases | FMC CORPORATION (US) | 1998-03-10 | — | — | US | claimed |
| WO-1997006173-A1 | HIGH PURITY FORMULATIONS OF HIGHLY SUBSTITUTED LITHIUM AMIDE BASES | FMC CORPORATION (US) | 1997-02-20 | — | — | WO | claimed |
| WO-1997002210-A2 | CONTAMINANT FREE ORGANOMETALLIC AMIDE COMPOSITIONS AND PROCESSES FOR MAKING SAME | FMC CORPORATION (US) | 1997-01-23 | — | — | WO | claimed |
| US-12637403-B2 | Access to chiral bisphenol (BPOL) ligands through desymmetrizing asymmetric ortho-selective mono-halogenation | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2026-05-26 | — | — | US | disclosed |
| EP-4727909-A1 | METHODS AND INTERMEDIATES FOR PREPARING COMPOUNDS | VIIV Healthcare UK (No.5) Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025215579-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250320213-A1 | Nitrogen-Containing Heterocyclic Compounds | PFIZER INC. (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| WO-2024257009-A1 | METHODS AND INTERMEDIATES FOR PREPARING COMPOUNDS | VIIV Healthcare UK (No.5) Limited (GB) | 2024-12-19 | — | — | WO | disclosed |
| CN-111193069-B | Electrolyte for electrochemical device, method for preparing the same, and electrochemical device | 三星电子株式会社 | 2024-11-01 | — | — | CN | disclosed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240166586-A1 | ACCESS TO CHIRAL BISPHENOL (BPOL) LIGANDS THROUGH DESYMMETRIZING ASYMMETRIC ORTHO-SELECTIVE MONO-HALOGENATION | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2024-05-23 | — | — | US | disclosed |
| US-11905237-B2 | Access to chiral bisphenol (BPOL) ligands through desymmetrizing asymmetric ortho-selective mono-halogenation | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2024-02-20 | — | — | US | disclosed |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11643398-B2 | Metallic salt containing anion having heterocyclic aromatic structure, method of preparing the metallic salt, and electrolyte and electrochemical device each including the metallic salt | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-05-09 | — | — | US | disclosed |
| EP-3657590-B1 | METALLIC SALT CONTAINING ANION HAVING HETEROCYCLIC AROMATIC STRUCTURE, METHOD OF PREPARING THE SAME, AS WELL AS ELECTROLYTE AND ELECTROCHEMICAL DEVICE EACH INCLUDING THE METALLIC SALT | SAMSUNG ELECTRONICS CO LTD (KR) | 2023-04-26 | — | — | EP | disclosed |
| CN-114539460-A | Method for synthesizing macromolecule loaded asymmetric catalyst | 哈尔滨工业大学（深圳） | 2022-05-27 | — | — | CN | disclosed |
| CN-114539460-A | Method for synthesizing macromolecule loaded asymmetric catalyst | 哈尔滨工业大学（深圳） | 2022-05-27 | — | — | CN | disclosed |
| CN-109336887-B | Benzimidazole chiral heterocyclic compound and preparation method and application thereof | 中山大学 | 2021-12-17 | — | — | CN | disclosed |
| US-20210300853-A1 | ACCESS TO CHIRAL BISPHENOL (BPOL) LIGANDS THROUGH DESYMMETRIZING ASYMMETRIC ORTHO-SELECTIVE MONO-HALOGENATION | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2021-09-30 | — | — | US | disclosed |
| EP-3409659-B1 | ADAMANTANE DERIVATIVE AND USE THEREOF | UNIV TOHOKU (JP) | 2020-12-30 | — | — | EP | disclosed |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-09-22 | — | — | US | disclosed |
| US-20200239494-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-07-30 | — | — | US | disclosed |
| EP-3657590-A1 | METALLIC SALT CONTAINING ANION HAVING HETEROCYCLIC AROMATIC STRUCTURE, METHOD OF PREPARING THE SAME, AS WELL AS ELECTROLYTE AND ELECTROCHEMICAL DEVICE EACH INCLUDING THE METALLIC SALT | Samsung Electronics Co., Ltd. (KR) | 2020-05-27 | — | — | EP | disclosed |
| CN-111193069-A | Metal salt, method for preparing metal salt, and electrolyte and electrochemical device each containing metal salt | 三星电子株式会社 | 2020-05-22 | — | — | CN | disclosed |
| US-20200157058-A1 | METALLIC SALT CONTAINING ANION HAVING HETEROCYCLIC AROMATIC STRUCTURE, METHOD OF PREPARING THE METALLIC SALT, AND ELECTROLYTE AND ELECTROCHEMICAL DEVICE EACH INCLUDING THE METALLIC SALT | SAMSUNG SDI CO., LTD. (KR) | 2020-05-21 | — | — | US | disclosed |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | EPICS THERAPEUTICS (BE) | 2020-05-14 | — | — | US | disclosed |
| WO-2019058290-A1 | IMPROVED PROCESS FOR THE PREPARATION OF OZANIMOD Α-AMINO COMPOUND | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-03-28 | — | — | WO | disclosed |
| US-20190055191-A1 | ADAMANTANE DERIVATIVE AND USE THEREOF | TOHOKU UNIVERSITY (JP) | 2019-02-21 | — | — | US | disclosed |
| CN-109336887-A | A kind of benzimidazole and chiral heterocycle class compound and its preparation method and application | 中山大学 | 2019-02-15 | — | — | CN | disclosed |
| EP-3409659-A1 | ADAMANTANE DERIVATIVE AND USE THEREOF | Tohoku University (JP) | 2018-12-05 | — | — | EP | disclosed |
| CN-108495841-A | Adamantane derivative and application thereof | 国立大学法人东北大学 | 2018-09-04 | — | — | CN | disclosed |
| US-8853390-B2 | Processes for preparing 1,2-substituted cyclopropyl derivatives | ABBVIE INC. (US) | 2014-10-07 | — | — | US | disclosed |
| WO-2014090918-A1 | PROCESS FOR THE ENANTIOMERIC ENRICHMENT OF DIARYLOXAZOLINE DERIVATIVES | NOVARTIS AG (CH) | 2014-06-19 | — | — | WO | disclosed |
| US-8541593-B2 | Process for making substituted 2-amino-thiazolones | AMGEN INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541593-B2 | Process for making substituted 2-amino-thiazolones | AMGEN INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8536345-B2 | Process for making substituted 2-amino-thiazolones | AMGEN INC. (US) | 2013-09-17 | — | — | US | disclosed |
| EP-2139879-B1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2012-07-11 | — | — | EP | disclosed |
| WO-2012037258-A1 | PROCESSES FOR PREPARING 1,2-SUBSTITUTED CYCLOPROPYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2012-03-22 | — | — | WO | disclosed |
| US-8084630-B2 | Process for the synthesis of ramelteon and its intermediates | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-12-27 | — | — | US | disclosed |
| US-7994355-B2 | Metallocene-based chiral phosphine or arsine ligands | SOLVIAS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-7994355-B2 | Metallocene-based chiral phosphine or arsine ligands | SOLVIAS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-20110160463-A1 | PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES | AMGEN INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110160463-A1 | PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES | AMGEN INC. | 2011-06-30 | — | — | US | disclosed |
| US-7964616-B2 | 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3S)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-20110045598-A1 | METHODS FOR DETERMINING ENANTIOMERIC PURITY WITH IMPROVED CHIRAL SELECTORS | BAYLOR UNIVERSITY | 2011-02-24 | — | — | US | disclosed |
| US-7884223-B2 | N-isopropylphenethylamine; N-(2,6-dimethoxybenzyl)1-phenethylamine; (R,R) N-(1-naphth-1-ylethyl)-1-phenethylamine; high activity; easily accessible | DSM IP ASSETS B.V. (NL) | 2011-02-08 | — | — | US | disclosed |
| US-20100280255-A1 | PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES | AMGEN INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280255-A1 | PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES | AMGEN INC. (US) | 2010-11-04 | — | — | US | disclosed |
| EP-1824868-B1 | CHIRAL COMPOUND SUITABLE AS A CATALYST FOR ASYMMETRIC TRANSFER HYDROGENATION | DSM IP ASSETS BV (NL) | 2010-06-02 | — | — | EP | disclosed |
| WO-2010008729-A2 | PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES | AMGEN INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-12 | — | — | US | disclosed |
| EP-2098519-A1 | Process for the synthesis of ramelteon and its intermediates | Teva Pharmaceutical Industries Ltd. (IL) | 2009-09-09 | — | — | EP | disclosed |
| EP-1805171-A4 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH CORP (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | US | disclosed |
| EP-1709054-B1 | METALLOCENE-BASED CHIRAL PHOSPHINE OR ARSINE LIGANDS | PHOENIX CHEMICALS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20080281106-A1 | Process for the Production of Asymmetric Transformation Catalysts | PHOENIX CHEMICALS LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080281106-A1 | Process for the Production of Asymmetric Transformation Catalysts | PHOENIX CHEMICALS LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080269529-A1 | Chiral Compound Suitable as a Catalyst for Asymmetric Transfer Hydrogenation | PATHEON HOLDINGS I B.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| US-20080234319-A1 | 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3S)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
| EP-1725570-B1 | PROCESS FOR THE PRODUCTION OF ASYMMETRIC TRANSFORMATION CATALYSTS | PHOENIX CHEMICALS LTD (GB) | 2008-08-13 | — | — | EP | disclosed |
| US-20070161762-A1 | Metallocene-based chiral phosphine or arsine ligands | PHOENIX CHEMICALS LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
| US-20070161762-A1 | Metallocene-based chiral phosphine or arsine ligands | PHOENIX CHEMICALS LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
| EP-1805171-A2 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | Athersys, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006034419-A2 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | ATHERSYS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006011052-A1 | METHOD FOR THE RACEMIZATION OF 2-TRIFLUORO-2H-CHROMENE-3-CARBOXYLIC ACIDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060020023-A1 | Racemization method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
| US-20060016683-A1 | Photoracamization method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
| US-20060020022-A1 | Enantioselective separation method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
| EP-0796849-B1 | NOVEL POLYCYCLIC AMINOPYRIDINE COMPOUNDS AS ACETYLCHOLINESTERASE INHIBITORS, PREPARATION PROCESS AND USE THEREOF | MEDICHEM SA (ES) | 2003-11-19 | — | — | EP | disclosed |
| US-6060617-A | REACTING AN ALKALI METAL HYDRIDE AND ALKALI METAL AMIDES WITH A SUBSTITUTED AMINE IN AN ETHER SOLVENT IN ABSENCE OF AN ELECTRON CARRIER TO PRODUCE AN ALKALI METAL AMIDE FREE OF ORGANIC CONTAMINANTS | FMC CORPORATION (US) | 2000-05-09 | — | — | US | disclosed |
| US-5965569-A | TREATING MEMORY DISORDERS SUCH AS SENILE DEMENTIA OR ALZHEIMER'S DISEASE | MEDICHEM, S.A. (ES) | 1999-10-12 | — | — | US | disclosed |
| EP-0843682-A1 | HIGH PURITY FORMULATIONS OF HIGHLY SUBSTITUTED LITHIUM AMIDE BASES | FMC CORPORATION (US) | 1998-05-27 | — | — | EP | disclosed |
| US-5726308-A | High purity formulations of highly substituted lithium amide bases | FMC CORPORATION (US) | 1998-03-10 | — | — | US | disclosed |
| EP-0796849-A1 | NOVEL POLYCYCLIC AMINOPYRIDINE COMPOUNDS AS ACETYLCHOLINESTERASE INHIBITORS, PREPARATION PROCESS AND USE THEREOF | Camps Garcia, Pelayo (ES) | 1997-09-24 | — | — | EP | disclosed |
| WO-1997006173-A1 | HIGH PURITY FORMULATIONS OF HIGHLY SUBSTITUTED LITHIUM AMIDE BASES | FMC CORPORATION (US) | 1997-02-20 | — | — | WO | disclosed |
| WO-1997002210-A2 | CONTAMINANT FREE ORGANOMETALLIC AMIDE COMPOSITIONS AND PROCESSES FOR MAKING SAME | FMC CORPORATION (US) | 1997-01-23 | — | — | WO | disclosed |
| WO-1995021824-A1 | 6-ARYL-(METHYL- OR METHYLIDENE)-QUINOL-2-ONE DERIVATIVES AS VOLTAGE GATED POTASSIUM CHANNEL BLOCKERS | JOHN WYETH & BROTHER LTD (GB) | 1995-08-17 | — | — | WO | disclosed |
| WO-1995021824-A1 | 6-ARYL-(METHYL- OR METHYLIDENE)-QUINOL-2-ONE DERIVATIVES AS VOLTAGE GATED POTASSIUM CHANNEL BLOCKERS | JOHN WYETH & BROTHER LTD (GB) | 1995-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (23 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | SIGMAR1 1432/4885ACP3 3113/4885CYP3A4 4/4885 |
| US-20190055191-A1 | ADAMANTANE DERIVATIVE AND USE THEREOF | BACE1, APP, PSEN1 | SIGMAR1 801/4885ACP3 3126/4885CYP3A4 1037/4885 |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | SIGMAR1 596/4885ACP3 2250/4885CYP3A4 1528/4885 |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | SIGMAR1 2891/4885ACP3 3658/4885CYP3A4 3215/4885 |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | GPR119, GPR65, GPR84 | SIGMAR1 1689/4885ACP3 986/4885CYP3A4 1298/4885 |
| US-20080281106-A1 | Process for the Production of Asymmetric Transformation Catalysts | OXSR1, OXGR1, OSR1 | SIGMAR1 6/4885ACP3 4631/4885CYP3A4 874/4885 |
| US-20200239494-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | SIGMAR1 2891/4885ACP3 3658/4885CYP3A4 3215/4885 |
| US-11643398-B2 | Metallic salt containing anion having heterocyclic aromatic structure, method of preparing the metallic salt, and electrolyte and electrochemical device each including the metallic salt | NAP1L1, AGTR1, AP2A1 | SIGMAR1 2649/4885ACP3 2342/4885CYP3A4 3889/4885 |
| US-20100280255-A1 | PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES | HSD11B1, HSD11B2, HSD17B1 | SIGMAR1 1821/4885ACP3 2994/4885CYP3A4 90/4885 |
| US-20070161762-A1 | Metallocene-based chiral phosphine or arsine ligands | OSGEP, PHOSPHO1, ITPA | SIGMAR1 2005/4885ACP3 51/4885CYP3A4 1701/4885 |
| US-20250320213-A1 | Nitrogen-Containing Heterocyclic Compounds | HRH4, HNMT, NNT | SIGMAR1 2650/4885ACP3 1347/4885CYP3A4 953/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | SIGMAR1 2891/4885ACP3 3658/4885CYP3A4 3215/4885 |
| US-12637403-B2 | Access to chiral bisphenol (BPOL) ligands through desymmetrizing asymmetric ortho-selective mono-halogenation | NR4A1, BRPF3, BPTF | SIGMAR1 358/4885ACP3 398/4885CYP3A4 463/4885 |
| US-20060020023-A1 | Racemization method | STS, SQLE, HAO2 | SIGMAR1 413/4885ACP3 1828/4885CYP3A4 66/4885 |
| US-20110160463-A1 | PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES | HSD11B1, HSD11B2, HSD17B1 | SIGMAR1 1514/4885ACP3 3266/4885CYP3A4 77/4885 |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | SIGMAR1 901/4885ACP3 3352/4885CYP3A4 5/4885 |
| US-20200157058-A1 | METALLIC SALT CONTAINING ANION HAVING HETEROCYCLIC AROMATIC STRUCTURE, METHOD OF PREPARING THE METALLIC SALT, AND ELECTROLYTE AND ELECTROCHEMICAL DEVICE EACH INCLUDING THE METALLIC SALT | NAP1L1, AP2A1, AGTR1 | SIGMAR1 2546/4885ACP3 2221/4885CYP3A4 3804/4885 |
| US-20080269529-A1 | Chiral Compound Suitable as a Catalyst for Asymmetric Transfer Hydrogenation | SLC30A6, SLC39A14, SLC30A5 | SIGMAR1 259/4885ACP3 2757/4885CYP3A4 2918/4885 |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | SIGMAR1 2891/4885ACP3 3658/4885CYP3A4 3215/4885 |
| US-20060016683-A1 | Photoracamization method | CYP3A43, CRY2, CRY1 | SIGMAR1 1056/4885ACP3 1317/4885CYP3A4 30/4885 |
| US-20240166586-A1 | ACCESS TO CHIRAL BISPHENOL (BPOL) LIGANDS THROUGH DESYMMETRIZING ASYMMETRIC ORTHO-SELECTIVE MONO-HALOGENATION | OSBP, BICRA, BRPF3 | SIGMAR1 777/4885ACP3 578/4885CYP3A4 114/4885 |
| US-20060020022-A1 | Enantioselective separation method | SLC7A1, SLC10A1, DHCR7 | SIGMAR1 843/4885ACP3 294/4885CYP3A4 86/4885 |
| US-20080234319-A1 | 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3S)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide; rheumatoid arthritis | CNKSR1, HRH4, HRH1 | SIGMAR1 574/4885ACP3 1952/4885CYP3A4 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.